» Articles » PMID: 34382802

Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology

Abstract

Due to increased lactate production during glucose metabolism, tumor cells heavily rely on efficient lactate transport to avoid intracellular lactate accumulation and acidification. Monocarboxylate transporter 4 (MCT4/SLC16A3) is a lactate transporter that plays a central role in tumor pH modulation. The discovery and optimization of a novel class of MCT4 inhibitors (hit ), identified by a cellular screening in MDA-MB-231, is described. Direct target interaction of the optimized compound with the cytosolic domain of MCT4 was shown after solubilization of the GFP-tagged transporter by fluorescence cross-correlation spectroscopy and microscopic studies. In vitro treatment with resulted in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells. Moreover, pharmacokinetic properties of allowed assessment of lactate modulation and antitumor activity in a mouse tumor model. Thus, represents a valuable tool for investigating selective MCT4 inhibition and its effect on tumor biology.

Citing Articles

MCT4 blockade increases the efficacy of immune checkpoint blockade.

Babl N, Decking S, Voll F, Althammer M, Sala-Hojman A, Ferretti R J Immunother Cancer. 2023; 11(10).

PMID: 37880183 PMC: 10603342. DOI: 10.1136/jitc-2023-007349.


Monocarboxylate transporter 4 promotes the migration of non‑cancerous L929 fibroblast cells by activating the IGF1/IGF1R/PIK3R3/SGK1 axis.

Zhou X, Wang S, Li Y, Zhao H, Han X, Yu Y Oncol Lett. 2023; 26(4):460.

PMID: 37745980 PMC: 10512108. DOI: 10.3892/ol.2023.14047.


Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors.

Dvorak V, Casiraghi A, Colas C, Koren A, Tomek T, Offensperger F Cell Chem Biol. 2023; 30(8):953-964.e9.

PMID: 37516113 PMC: 10437005. DOI: 10.1016/j.chembiol.2023.06.029.


Target 2035 - an update on private sector contributions.

Ackloo S, Antolin A, Bartolome J, Beck H, Bullock A, Betz U RSC Med Chem. 2023; 14(6):1002-1011.

PMID: 37360399 PMC: 10285765. DOI: 10.1039/d2md00441k.


Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis.

Sheng G, Gao Y, Wu H, Liu Y, Yang Y J Orthop Surg Res. 2023; 18(1):131.

PMID: 36814318 PMC: 9948327. DOI: 10.1186/s13018-023-03623-w.